NOVARTIS AG

Drug Name	Phase	Indication	Designations	Patent
trivalent split influenza vaccine	Phase 3	Seasonal Influenza	-	-
dovitinib	Phase 3	Solid Tumors	-	-
Focalin XR	Phase 3	ADHD	-	-
Tiotropium	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
Everolimus + reduced tacrolimus	Phase 3	Liver Transplantation	-	-
Octreotide	Phase 3	Acromegaly	-	-
Pelacarsen	Phase 3	Atherosclerotic Cardiovascular Disease (ASCVD)	-	-
Enteric-Coated Mycophenolate Sodium	Phase 3	Prevention of Acute Rejection After Kidney Transplantation	-	-
Pazopanib	Phase 3	Ovarian Cancer	-	-
Pimecrolimus	Phase 3	Keratoconjunctivitis Sicca	-	-
MenACWY-CRM	Phase 3	Meningococcal Disease	-	-
LCQ908	Phase 3	Familial Chylomicronemia Syndrome (FCS)	-	-
inclisiran sodium	Phase 3	Hypercholesterolemia	-	-
Imatinib	Phase 3	Chronic Myelogenous Leukemia in Chronic Phase	-	-
Darifenacin	Phase 3	Overactive Bladder Syndrome	-	-
Tamoxifen	Phase 3	Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women	-	-
Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine	Phase 3	Swine-Origin Influenza A H1N1 Virus	-	-
Anastrozole	Phase 3	Breast Cancer	-	-
rivastigmine transdermal patch	Phase 3	Alzheimer's Disease	-	-
Pasireotide	Phase 3	Cushing's Disease	-	-
Indacaterol 150 μg	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)	Phase 3	Parkinson's Disease	-	-
Octreotide LAR	Phase 3	Acromegaly	-	-
Agomelatine (AGO178C)	Phase 3	Major Depressive Disorder	-	-
osilodrostat	Phase 3	Cushings Disease	-	-
Ofatumumab	Phase 3	Relapsing Multiple Sclerosis	-	-
Letrozole	Phase 3	Breast Cancer	-	-
LCZ696	Phase 3	Hypertension	-	-
Secukinumab (75 mg)	Phase 3	Psoriatic Arthritis	-	-
Canakinumab pre-filled syringe	Phase 3	Acute Gouty Arthritis	-	-
amlodipine	Phase 3	Hypertension	-	-
Sunitinib	Phase 3	Carcinoma, Renal Cell	-	-
Meningococcal ACWY conjugate vaccine	Phase 3	Bacterial Meningitis	-	-
Fingolimod 1.25 mg	Phase 3	Multiple Sclerosis	-	-
Diclofenac topical sodium gel 1%	Phase 3	Osteoarthritis	-	-
Pelabresib	Phase 3	Myelofibrosis	-	-
TQJ230	Phase 3	Cardiovascular Disease and Lipoprotein(a)	-	-
Physicians' Choice	Phase 3	Leukaemia	-	-
Olmesartan	Phase 3	Essential Hypertension	-	-
Remibrutinib	Phase 3	Chronic Spontaneous Urticaria	-	-
Siponimod	Phase 3	Multiple Sclerosis (MS)	-	-
valsartan plus hydrochlorothiazide	Phase 3	Hypertension	-	-
Ranibizumab (RFB002)	Phase 3	Diabetic Macular Edema	-	-
Dabrafenib	Phase 3	Neoplasms, Brain	-	-
Formoterol (12 µg b.i.d.)	Phase 3	Pulmonary Disease, Chronic Obstructive	-	-
Trametinib	Phase 3	Melanoma and Brain Metastases	-	-
Indacaterol 150 µg	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
valsartan + amlodipine	Phase 3	Hypertension	-	-
Pasireotide LAR	Phase 3	Acromegaly	-	-
Nilotinib (AMN107)	Phase 3	Gastrointestinal Stromal Tumor (GIST)	-	-
Ustekinumab	Phase 3	Psoriatic Arthritis	-	-
RAD001	Phase 3	Carcinoma	-	-
NVA237	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
Alcon Investigational Agent	Phase 3	Open-Angle Glaucoma	-	-
Anecortave Acetate 15 mg sterile suspension	Phase 3	Macular Degeneration	-	-
Secukinumab 300 mg	Phase 3	Chronic Scalp Psoriasis	-	-
Salmeterol 50 μg	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
QAW039	Phase 3	Asthma	-	-
Lumiracoxib	Phase 3	Knee Osteoarthritis	-	-
Licarbazepine	Phase 3	Bipolar Disorder	-	-
EXE844 Sterile Otic Suspension, 0.3%	Phase 3	Otitis Media With Effusion in Children	-	-
Onasemnogene Abeparvovec-xioi	Phase 3	Spinal Muscular Atrophy Type I	-	-
Canakinumab	Phase 3	Rheumatoid Arthritis	-	-
AIN457	Phase 3	Plaque-type Psoriasis	-	-
Enteric-coated Mycophenolate sodium (EC-MPS)	Phase 3	Liver Transplantation	-	-
Artemether-lumefantrine	Phase 3	Plasmodium Falciparum Malaria	-	-
Valsartan/amlodipine 80/5 mg	Phase 3	Hypertension	-	-
MF59-eH1N1_f	Phase 3	Influenza	-	-
Valsartan	Phase 3	Hypertension	-	-
iptacopan	Phase 3	IC-MPGN	-	-
Nilotinib	Phase 3	Chronic Myelogenous Leukemia	-	-
rMenB+OMV NZ	Phase 3	Prevention of the Meningococcal Disease	-	-
FTY720	Phase 3	Multiple Sclerosis	-	-
Brolucizumab	Phase 3	Diabetic Macular Edema	-	-
valsartan/amlodipine	Phase 3	Hypertension	-	-
Panobinostat	Phase 3	Cutaneous T-Cell Lymphoma	-	-
Nepafenac Ophthalmic Suspension, 0.1%	Phase 3	Cataract	-	-
Haemophilus influenzae type b (Hib) vaccine	Phase 3	Haemophilus Influenzae Type b (Hib) Infection	-	-
NIS793	Phase 3	Metastatic Pancreatic Ductal Adenocarcinoma	-	-
Hydrochlorothiazide	Phase 3	Hypertension	-	-
MenACWY-CRM197	Phase 3	Meningitis	-	-
vildagliptin + metformin	Phase 3	Diabetes Mellitus, Type 2	-	-
Basiliximab	Phase 3	Liver Transplant	-	-
Indacaterol 300 µg	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
BION-1301	Phase 3	IgA Nephropathy	-	-
Prednisone	Phase 3	Renal Transplantation	-	-
LNP023	Phase 3	Paroxysmal Nocturnal Hemoglobinuria (PNH)	-	-
Ruxolitinib	Phase 3	Cytokine Storm (Covid-19)	-	-
pioglitazone	Phase 3	Diabetes Mellitus, Type 2	-	-
eltrombopag	Phase 3	Immune Thrombocytopenic Purpura (ITP)	-	-
Ligelizumab	Phase 3	Chronic Spontaneous Urticaria	-	-
AMN107	Phase 3	Leukemia, Myeloid, Chronic	-	-
Influenza virus vaccine	Phase 3	Influenza	-	-
QAB149	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
Tobramycin inhalation powder	Phase 3	Pulmonary Infections	-	-
LOU064	Phase 3	Chronic Spontaneous Urticaria	-	-
Bosutinib	Phase 3	Chronic Myelogenous Leukemia	-	-
Metformin	Phase 3	Diabetes Mellitus, Type 2	-	-
agomelatine	Phase 3	Major Depressive Disorder (MDD)	-	-
Lapatinib	Phase 3	Breast Neoplasms	-	-
Everolimus	Phase 3	Tuberous Sclerosis	-	-
Famciclovir	Phase 3	Herpes Labialis	-	-
Certoparin	Phase 3	Renal Dialysis	-	-
LCZ696 (Sacubitril/Valsartan)	Phase 3	Chronic Heart Failure With Reduced Ejection Fraction	-	-
Inclisiran	Phase 3	Atherosclerotic Cardiovascular Disease	-	-
Alpelisib	Phase 3	Breast Neoplasms	-	-
Glimepiride	Phase 3	Type II Diabetes Mellitus	-	-
ACZ885	Phase 3	Pulmonary Sarcoidosis	-	-
asciminib	Phase 3	Chronic Myelogenous Leukemia - Chronic Phase	-	-
Glycopyrronium bromide	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
Exemestane	Phase 3	Breast Cancer	-	-
Everolimus (RAD001)	Phase 3	Renal Transplantation	-	-
Salbutamol/albuterol	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
Lansoprazole	Phase 3	Frequent Heartburn	-	-
Aliskiren/HCTZ	Phase 3	Hypertension	-	-
Enalapril	Phase 3	Hypertension	-	-
Paclitaxel	Phase 3	Breast Cancer	-	-
secukinumab 150 mg	Phase 3	Moderate to Severe Chronic Plaque-type Psoriasis	-	-
QVA149	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
VAY736	Phase 3	Sjogren Syndrome	-	-
Certican	Phase 3	Kidney Transplantation	-	-
Vildagliptin AM	Phase 3	Diabetes Mellitus, Type 2	-	-
vildagliptin	Phase 3	Diabetes Mellitus, Type 2	-	-
ranibizumab	Phase 3	Neovascular Age-related Macular Degeneration	-	-
Rivastigmine	Phase 3	Vascular Dementia	-	-
terbinafine	Phase 3	Onychomycosis	-	-
TIVc	Phase 3	Influenza	-	-
Sitagliptin	Phase 3	Diabetes Mellitus, Type 2	-	-
Monovalent A/H1N1 influenza vaccine	Phase 3	Pandemic Influenza	-	-
Omalizumab	Phase 3	Asthma	-	-
QVM149	Phase 3	Asthma	-	-
CTL019	Phase 3	Acute Lymphoblastic Leukemia	-	-
imatinib mesylate	Phase 3	Leukemia	-	-
secukinumab	Phase 3	Juvenile Psoriatic Arthritis	-	-
deferasirox	Phase 3	Non-transfusion Dependent Thalassemia	-	-
Ranibizumab 0.5 mg	Phase 3	Proliferative Diabetic Retinopathy (PDR)	-	-
telbivudine	Phase 3	Chronic Hepatitis B	-	-
Meningococcal C Conjugate Vaccine	Phase 3	Prevention of Meningococcal Infection	-	-
Indacaterol 300 μg	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
RLX030	Phase 3	Acute Heart Failure	-	-
Tegaserod	Phase 3	Dyspepsia	-	-
secukinumab (AIN457)	Phase 3	Rheumatoid Arthritis	-	-
Ianalumab	Phase 3	Primary Immune Thrombocytopenia (ITP)	-	-
aliskiren	Phase 3	Hypertension	-	-
Formoterol	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
Fingolimod	Phase 3	Multiple Sclerosis	-	-
Mycophenolate mofetil (MMF)	Phase 3	Kidney Transplantation	-	-
Olmesartan medoxomil	Phase 3	Hypertension	-	-
Tacrolimus	Phase 3	Kidney Diseases	-	-
Indacaterol	Phase 3	Asthma	-	-
Zoledronic acid	Phase 3	Breast Cancer With Bone Metastasis	-	-
TIV	Phase 2	Human Influenza	-	-
Investigator choice of chemotherapy	Phase 2	Nasopharyngeal Carcinoma	-	-
Sandostatin LAR Depot	Phase 2	Primary Insulin Hypersecretion	-	-
LFG316	Phase 2	Neovascular Age-elated Macular Degeneration (Wet AMD)	-	-
Hydrochlorothiazide (HCTZ)	Phase 2	Essential Hypertension	-	-
inhaled corticosteroid therapy	Phase 2	Bronchial Asthma	-	-
Midostaurin	Phase 2	Acute Myeloid Leukemia	-	-
Iptacopan (LNP023)	Phase 2	Age-Related Macular Degeneration	-	-
Nidufexor	Phase 2	Diabetic Nephropathy	-	-
DNK333 5 mg	Phase 2	Pruritus in Patients With Atopic Dermatitis	-	-
ECMPS-IEM	Phase 2	Detection Accuracy	-	-
ramipril	Phase 2	Heart Failure	-	-
LYS006 20 mg	Phase 2	Inflammatory Acne	-	-
AEE788	Phase 2	Glioblastoma Multiforme	-	-
Clozapine	Phase 2	Schizophrenia	-	-
prednisolone	Phase 2	Healthy	-	-
QMF149	Phase 2	COPD	-	-
Cyclosporine	Phase 2	Severe Aplastic Anemia	-	-
Trivalent influenza virus vaccine (TIV)	Phase 2	Human Influenza	-	-
LDK378	Phase 2	Non-Small-Cell Lung Cancer	-	-
Serelaxin	Phase 2	Acute Heart Failure	-	-
LIK066	Phase 2	Polycystic Ovary Syndrome	-	-
LEE011	Phase 2	Tumors With CDK4/6 Pathway Activation	-	-
CMK389	Phase 2	Pulmonary Sarcoidosis	-	-
crizanlizumab	Phase 2	Sickle Cell Disease (SCD)	-	-
Bendamustine	Phase 2	Chronic Lymphocytic Leukemia (CLL)	-	-
Mometasone furoate	Phase 2	Asthma	-	-
Atrasentan	Phase 2	IgA Nephropathy	-	-
AFQ056	Phase 2	Dyskinesias	-	-
TIN816 70 mg lyophilisate powder	Phase 2	Acute Kidney Injury Due to Sepsis	-	-
epothilone b	Phase 2	Colorectal Neoplasms	-	-
JDQ443	Phase 2	Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation	-	-
[177Lu]Lu-PSMA-617	Phase 2	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	-	-
LAG525	Phase 2	Melanoma	-	-
QGE031	Phase 2	Asthma	-	-
BGG492	Phase 2	Adrenocortical Adenoma	-	-
rMenB	Phase 2	Meningococcal Disease	-	-
PDR001	Phase 2	Small Cell Lung Cancer	-	-
VHB937	Phase 2	Alzheimer's Disease	-	-
Adjuvanted H5N1 pandemic influenza vaccine	Phase 2	Pandemic H5N1 Influenza	-	-
indacaterol/glycopyrrolate	Phase 2	Chronic Obstructive Pulmonary Disease (COPD)	-	-
Adjuvanted influenza vaccine	Phase 2	Influenza Disease	-	-
BAF312	Phase 2	Relapsing Remitting Multiple Sclerosis	-	-
MAS825	Phase 2	Coronary Heart Disease	-	-
MCS110	Phase 2	Triple Negative Breast Cancer	-	-
influenza vaccine	Phase 2	Influenza	-	-
LCI699	Phase 2	Hypertension	-	-
AQW051	Phase 2	Schizophrenia	-	-
DFV890	Phase 2	Symptomatic Knee Osteoarthritis	-	-
TCH346	Phase 2	Amyotrophic Lateral Sclerosis	-	-
DNK333	Phase 2	Irritable Bowel Syndrome	-	-
LDE225	Phase 2	Medulloblastoma	-	-
AEB071	Phase 2	Kidney Transplantation	-	-
CDZ173	Phase 2	Primary Sjögren's Syndrome	-	-
AAE581	Phase 2	Osteoporosis	-	-
Monovalent inactivated influenza vaccine	Phase 2	Prepandemic Influenza Vaccine	-	-
Triamcinolone acetonide	Phase 2	Acute Gout	-	-
PKN605	Phase 2	Atrial Fibrillation	-	-
rapcabtagene autoleucel (YTB323)	Phase 2	Relapsing Multiple Sclerosis	-	-
YTB323	Phase 2	Systemic Lupus Erythematosus	-	-
ICL670	Phase 2	Sickle Cell Disease	-	-
Ribociclib	Phase 2	Breast Cancer	-	-
BYM338	Phase 2	Sporadic Inclusion Body Myositis	-	-
CJM112	Phase 2	Asthma	-	-
CFZ533	Phase 2	Sjögren Syndrome	-	-
Capmatinib	Phase 2	Non-Small Cell Lung Cancer (NSCLC)	-	-
LYS006	Phase 2	Hidradenitis Suppurativa	-	-
QAX576	Phase 2	Allergic Rhinitis	-	-
Cryptosporidium parvum oocysts (ABO809)	Phase 2	Cryptosporidiosis	-	-
HSC835	Phase 2	Single Umbilical Cord Blood Transplantation	-	-
rapcabtagene autoleucel	Phase 2	Lupus Erythematosus, Systemic	-	-
cetuximab	Phase 2	KRAS G12C Mutant Solid Tumors	-	-
ranibizumab 0.5mg	Phase 2	Choroidal Neovascularisation	-	-
Vinorelbine	Phase 2	Cancer	-	-
LDE225 0.25%	Phase 2	Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients	-	-
bimagrumab	Phase 2	Muscle Wasting (Atrophy) After Hip Fracture Surgery	-	-
SBR759	Phase 2	Chronic Kidney Disease	-	-
Surface Antigen, Inactivated, Influenza (form.2006-07)	Phase 2	Influenza	-	-
BKM120	Phase 2	HER2-positive Newly Diagnosed, Primary Breast Cancer	-	-
GIA632	Phase 2	Non-segmental Vitiligo	-	-
Patupilone	Phase 2	Hepatocellular Carcinoma	-	-
LHW090	Phase 2	Chronic Kidney Disease (CKD)	-	-
Aliskiren 300 mg	Phase 2	Post Acute Coronary Syndrome	-	-
Spartalizumab	Phase 2	Advanced Hepatocellular Carcinoma	-	-
INC424	Phase 2	Primary Myelofibrosis	-	-
Capecitabine	Phase 2	Breast Cancer	-	-
Eltrombopag 12.5 mg	Phase 2	Cytopaenia	-	-
CAD106	Phase 2	Alzheimer Disease	-	-
fluticasone propionate/salmeterol	Phase 2	Asthma	-	-
AHU377	Phase 2	Systolic Hypertension	-	-
Investigational Treatment	Phase 2	Actinic Keratosis	-	-
Seasonal Influenza Vaccine	Phase 2	Influenza	-	-
Deferasirox (ICL670)	Phase 2	Iron Overload	-	-
QBW251	Phase 2	Chronic Obstructive Pulmonary Disease, COPD	-	-
TKI258	Phase 2	Melanoma	-	-
Investigational new drug, company code: BGG492	Phase 2	Seizures	-	-
Montelukast	Phase 2	Allergic Rhinitis	-	-

Regulatory Approvals

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

NOVARTIS AG

Market Overview

NVSEF News

Catalyst Timeline

Ianalumab Phase 3 Results Expected

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals